FDA Panel Backs Ketamine-Like Drug for Depression

Share this content:
FDA Panel Backs Ketamine-Like Drug for Depression
FDA Panel Backs Ketamine-Like Drug for Depression

WEDNESDAY, Feb. 13, 2019 (HealthDay News) -- An expert panel for the U.S. Food and Drug Administration has endorsed a drug for major depressive disorder that is a close relative to ketamine.

If approved by the FDA, the new drug known as esketamine would be available to patients who have not found relief with at least two other antidepressants. The Tuesday vote was 14 to 2, with one member abstaining, according to CNN. The FDA does not have to follow the recommendations of its expert panels, but it typically does. A decision is expected in early March.

Made by Janssen, a division of Johnson & Johnson, esketamine is a nasal spray medication that targets different pathways in the brain than other antidepressants do. Unlike antidepressants that can take four to six weeks to take effect, esketamine's benefits can be felt within hours or days, the FDA said. Therefore, it is likely that esketamine might be used effectively in conjunction with an antidepressant, the agency added.

Despite the panel's approval, two of five key studies of esketamine failed to meet their primary goals. When taking esketamine, some patients experienced sedation, blood pressure spikes, and dissociation within two hours of taking the drug, CNN reported. Six patients died while taking esketamine in those trials, including three suicides, but agency documents concluded that "it is difficult to consider these deaths as drug-related." Because of those caveats, patients will not be allowed to purchase the drug at a local pharmacy; instead, a health care professional would have to monitor the person during the first two hours, the news service said.

CNN Article

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Operative Treatment Seems Most Effective for Adult Lumbar Scoliosis

Operative Treatment Seems Most Effective for Adult Lumbar ...

Nonoperative tx advised if patient satisfied with spine-related health; surgery may improve outcomes

Intervention Can Reduce Orders for Inpatient Urine Cultures

Intervention Can Reduce Orders for Inpatient Urine Cultures

Intervention includes notifications to providers, changes to order sets, new urine culture reflex tests

Odds of Receiving Tx for CAD Up With Medicare Advantage

Odds of Receiving Tx for CAD Up With ...

However, no significant difference seen in intermediate outcomes for those enrolled in MA, FFS Medicare

is free, fast, and customized just for you!




Already a member?

Sign In Now »